Kiniksa Pharmaceuticals International, plc KNSA Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $278.14M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 150.1% year-over-year, from $111.21M to $278.14M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 3.5% compound annual growth rate (CAGR), from $209.44M to $248.48M.
- What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
- This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.